Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Who is Retatrutide 40 mg for Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA Triple GLP-1 / GIP / glucagon agonist a unique mechanism of action For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect Strictly under medical supervision Retatrutide 40 mg compared to other doses Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023) Compared to Mounjaro 15 mg (~2226%) a similar effect, but with a triple mechanism Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure No final Phase 3 results yet efficacy and safety are still being confirmed FAQ about Retatrutide 40 mg (ALLUVI) 1 ALLUVI Retatrutide injection pen (40 mg total, dial mechanism up to 10 mg per dose), 12 single-use ALLUVI needles and dosing instructions (Dosage Guide) with step-by-step schedule from 2.5 mg to 10 mg
So when you ask yourself, Why am I so tired during my period?, the short answer is: because your body is busy being a biochemical superhero
The sulphurous burps some Ozempic patients describe are caused by foods stuck in slow-emptying stomachs typically high-fat, high-protein meals such as red meat, eggs in excess, or fatty fried foods
Weight loss can benefit your overall health in many ways
